NASDAQ:CRSP
CRISPR Therapeutics Stock News
$53.91
+0.180 (+0.335%)
At Close: Apr 26, 2024
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
07:06pm, Monday, 22'nd Apr 2024
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.02, representing a -0.05% change from its previous close.
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
04:30pm, Monday, 22'nd Apr 2024
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis
Bullish Trendline Has Never Failed Crispr Therapeutics Stock
12:58pm, Wednesday, 17'th Apr 2024
Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10.
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
10:01am, Wednesday, 17'th Apr 2024
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
3 Magnificent Stocks That Could Double or More by 2030
08:47am, Saturday, 13'th Apr 2024
CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
01:10pm, Thursday, 11'th Apr 2024
Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
07:06pm, Tuesday, 09'th Apr 2024
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
05:03am, Friday, 05'th Apr 2024
Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 03'rd Apr 2024
ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
08:00am, Monday, 01'st Apr 2024
ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis
Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans
03:03am, Saturday, 30'th Mar 2024
CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships, positioning it at the forefront of life science innovation. The approval of CASGEVY, the first CRISPR-based med
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
08:39am, Thursday, 28'th Mar 2024
Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
07:16pm, Monday, 25'th Mar 2024
CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
06:45am, Saturday, 23'rd Mar 2024
Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.
3 Biopharma Stocks Predicted to Soar in Q2 2024
01:49pm, Wednesday, 20'th Mar 2024
Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for